TNSN07224A1 - Combinations of therapeutic agents for treating cancer - Google Patents
Combinations of therapeutic agents for treating cancerInfo
- Publication number
- TNSN07224A1 TNSN07224A1 TNP2007000224A TNSN07224A TNSN07224A1 TN SN07224 A1 TNSN07224 A1 TN SN07224A1 TN P2007000224 A TNP2007000224 A TN P2007000224A TN SN07224 A TNSN07224 A TN SN07224A TN SN07224 A1 TNSN07224 A1 TN SN07224A1
- Authority
- TN
- Tunisia
- Prior art keywords
- inhibitor
- kinase inhibitor
- combinations
- therapeutic agents
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 229940123729 mTOR kinase inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 abstract 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 abstract 1
- -1 platin compound Chemical class 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
- 239000002525 vasculotropin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63643904P | 2004-12-15 | 2004-12-15 | |
| PCT/US2005/044993 WO2006065780A2 (en) | 2004-12-15 | 2005-12-13 | Combinations of therapeutic agents for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN07224A1 true TNSN07224A1 (en) | 2008-11-21 |
Family
ID=36463409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2007000224A TNSN07224A1 (en) | 2004-12-15 | 2007-06-14 | Combinations of therapeutic agents for treating cancer |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8975248B2 (enExample) |
| EP (1) | EP1827437B1 (enExample) |
| JP (1) | JP5345323B2 (enExample) |
| KR (1) | KR101367516B1 (enExample) |
| CN (1) | CN101080227B (enExample) |
| AT (1) | ATE531371T1 (enExample) |
| AU (1) | AU2005316652B2 (enExample) |
| BR (1) | BRPI0515774A (enExample) |
| CA (1) | CA2589521C (enExample) |
| CY (1) | CY1112368T1 (enExample) |
| DK (1) | DK1827437T3 (enExample) |
| ES (1) | ES2374828T3 (enExample) |
| HR (1) | HRP20110960T1 (enExample) |
| IL (1) | IL183595A0 (enExample) |
| MA (1) | MA29096B1 (enExample) |
| MX (1) | MX2007007212A (enExample) |
| NO (1) | NO20073552L (enExample) |
| NZ (1) | NZ555370A (enExample) |
| PL (1) | PL1827437T3 (enExample) |
| PT (1) | PT1827437E (enExample) |
| RU (1) | RU2400232C2 (enExample) |
| SI (1) | SI1827437T1 (enExample) |
| TN (1) | TNSN07224A1 (enExample) |
| TW (1) | TW200628151A (enExample) |
| WO (1) | WO2006065780A2 (enExample) |
| ZA (1) | ZA200704701B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122012021252B8 (pt) | 2002-09-06 | 2021-05-25 | Cerulean Pharma Inc | polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência |
| JP5345323B2 (ja) | 2004-12-15 | 2013-11-20 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 癌を処置するための治療剤の組合せ |
| JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
| US9006224B2 (en) * | 2005-11-21 | 2015-04-14 | Novartis Ag | Neuroendocrine tumor treatment |
| WO2007094026A1 (en) * | 2006-02-17 | 2007-08-23 | Paolo La Colla | Prophylactic and/or therapeutic treatment of proliferative and conformational diseases |
| EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
| EP2606890A1 (en) * | 2006-04-05 | 2013-06-26 | Novartis AG | Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer |
| WO2007115286A2 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CN101837129B (zh) * | 2009-03-19 | 2012-12-12 | 鼎泓国际投资（香港）有限公司 | 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用 |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| WO2011133479A2 (en) * | 2010-04-19 | 2011-10-27 | Niiki Pharma Inc. | Combination therapy with a proteasome inhibitor and a gallium complex |
| HUE042801T2 (hu) | 2010-11-12 | 2019-07-29 | Pharma Mar Sa | Kombinációs terápia mitózisgátlóval |
| CN102731516B (zh) * | 2011-04-07 | 2014-07-02 | 宁波天衡药业股份有限公司 | 一类具有抗肿瘤活性的喜树碱衍生物 |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| DK3127545T3 (da) * | 2014-04-04 | 2020-08-10 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer |
| WO2016201481A1 (en) | 2015-06-15 | 2016-12-22 | Newsouth Innovations Pty Limited | Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors |
| CN107951888A (zh) * | 2017-12-19 | 2018-04-24 | 天津科技大学 | 阿法替尼与10-羟基喜树碱的药物组合及其应用 |
| CN109091480A (zh) * | 2018-09-19 | 2018-12-28 | 天津科技大学 | 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途 |
| CN113195000A (zh) * | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| CN111789903A (zh) * | 2019-04-08 | 2020-10-20 | 石小和 | 治疗尿道癌的药物组合物及其制备方法 |
| PH12022551216A1 (en) | 2019-11-21 | 2023-07-17 | Pharma Mar Sa | Methods of treating small cell lung cancer with lurbinectedin formulations |
| CN120695174A (zh) * | 2021-07-01 | 2025-09-26 | 江苏先声生物制药有限公司 | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |
| WO2023165603A1 (en) * | 2022-03-03 | 2023-09-07 | Zai Lab (Shanghai) Co., Ltd. | Dna-pk inhibitor and combination use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08169825A (ja) * | 1994-12-15 | 1996-07-02 | Tanaka Kikinzoku Kogyo Kk | 抗癌剤の併用投与方法及び併用可能な抗癌剤 |
| DE69531722T2 (de) | 1994-11-11 | 2004-07-01 | Debiopharm S.A. | Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| ATE216998T1 (de) * | 1999-03-09 | 2002-05-15 | Sigma Tau Ind Farmaceuti | Camptothecin-derivate mit antitumor-wirkung |
| US7105492B2 (en) | 1999-03-09 | 2006-09-12 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| WO2003037897A2 (en) | 2001-10-29 | 2003-05-08 | Novartis Ag | Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| EP1545544A2 (en) * | 2002-07-11 | 2005-06-29 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
| AU2004241729A1 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| EP1761281A1 (en) * | 2004-06-04 | 2007-03-14 | Pfizer Products Incorporated | Method for treating abnormal cell growth |
| JP5345323B2 (ja) | 2004-12-15 | 2013-11-20 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 癌を処置するための治療剤の組合せ |
| JP4702322B2 (ja) | 2006-12-14 | 2011-06-15 | トヨタ自動車株式会社 | 内燃機関の制御装置 |
-
2005
- 2005-12-13 JP JP2007546818A patent/JP5345323B2/ja not_active Expired - Fee Related
- 2005-12-13 PT PT05853820T patent/PT1827437E/pt unknown
- 2005-12-13 WO PCT/US2005/044993 patent/WO2006065780A2/en not_active Ceased
- 2005-12-13 ES ES05853820T patent/ES2374828T3/es not_active Expired - Lifetime
- 2005-12-13 PL PL05853820T patent/PL1827437T3/pl unknown
- 2005-12-13 BR BRPI0515774-9A patent/BRPI0515774A/pt active Search and Examination
- 2005-12-13 CN CN2005800429798A patent/CN101080227B/zh not_active Expired - Lifetime
- 2005-12-13 MX MX2007007212A patent/MX2007007212A/es active IP Right Grant
- 2005-12-13 EP EP05853820A patent/EP1827437B1/en not_active Expired - Lifetime
- 2005-12-13 AT AT05853820T patent/ATE531371T1/de active
- 2005-12-13 US US11/720,776 patent/US8975248B2/en not_active Expired - Fee Related
- 2005-12-13 AU AU2005316652A patent/AU2005316652B2/en not_active Ceased
- 2005-12-13 CA CA2589521A patent/CA2589521C/en not_active Expired - Fee Related
- 2005-12-13 SI SI200531442T patent/SI1827437T1/sl unknown
- 2005-12-13 HR HR20110960T patent/HRP20110960T1/hr unknown
- 2005-12-13 NZ NZ555370A patent/NZ555370A/en not_active IP Right Cessation
- 2005-12-13 RU RU2007126978/14A patent/RU2400232C2/ru not_active IP Right Cessation
- 2005-12-13 KR KR1020077013401A patent/KR101367516B1/ko not_active Expired - Fee Related
- 2005-12-13 DK DK05853820.8T patent/DK1827437T3/da active
- 2005-12-14 TW TW094144288A patent/TW200628151A/zh unknown
-
2007
- 2007-05-31 IL IL183595A patent/IL183595A0/en unknown
- 2007-06-07 ZA ZA200704701A patent/ZA200704701B/xx unknown
- 2007-06-14 TN TNP2007000224A patent/TNSN07224A1/fr unknown
- 2007-06-18 MA MA29998A patent/MA29096B1/fr unknown
- 2007-07-09 NO NO20073552A patent/NO20073552L/no not_active Application Discontinuation
-
2012
- 2012-01-20 CY CY20121100074T patent/CY1112368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183595A0 (en) | Combinations of therapeutic agents for treating cancer | |
| NO20061777L (no) | Kombinasjon av en VEGF-resptorinhibitor og er kjemopteraputisk middel | |
| ES2654623T3 (es) | Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan | |
| Ferrario et al. | Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| RU2008152435A (ru) | Композиции и способы регулирования развития сосудов | |
| MXPA02011379A (es) | Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb. | |
| MXPA02011913A (es) | Triazolopirimidinas sustituidas como agentes anticancer. | |
| WO2004037341A3 (en) | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy | |
| JP2007523862A5 (enExample) | ||
| AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
| BG108072A (en) | The use of epothilone derivatives for the treatment of refractory tumors | |
| EA200801309A1 (ru) | ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ | |
| AU2003244762A1 (en) | Methods and compositions for intravesical therapy of bladder cancer | |
| JP2014144979A (ja) | 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤 | |
| ATE381930T1 (de) | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor | |
| RU99126204A (ru) | Способ лечения рака легкого | |
| AR063459A1 (es) | Metodo para administrar un inhibidor de aurora en el tratamiento del cancer | |
| RU2005110536A (ru) | Способ лечения рака | |
| TW200503798A (en) | Arsenic-containing pharmaceutical composition for treatment of tumor/cancer in conjunction with radiation therapy | |
| DK1687642T3 (da) | Screeningsfremgangsmåder til kombinationer af biologiske forbindelser | |
| EA202092513A1 (ru) | Комбинированная терапия |